TWI752036B - 編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途 - Google Patents

編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途 Download PDF

Info

Publication number
TWI752036B
TWI752036B TW106118838A TW106118838A TWI752036B TW I752036 B TWI752036 B TW I752036B TW 106118838 A TW106118838 A TW 106118838A TW 106118838 A TW106118838 A TW 106118838A TW I752036 B TWI752036 B TW I752036B
Authority
TW
Taiwan
Prior art keywords
vegf
modified rna
formulation
composition
saline buffer
Prior art date
Application number
TW106118838A
Other languages
English (en)
Chinese (zh)
Other versions
TW201808325A (zh
Inventor
萊夫 K. 帕林德
蕾吉娜 D. 弗里切丹尼爾森
肯尼 M. 漢森
黎明 甘
強納森 克拉克
安夏洛特 E. 艾格尼爾
肯尼斯 R. 簡
Original Assignee
美商瑪德那特克斯股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑪德那特克斯股份有限公司 filed Critical 美商瑪德那特克斯股份有限公司
Publication of TW201808325A publication Critical patent/TW201808325A/zh
Application granted granted Critical
Publication of TWI752036B publication Critical patent/TWI752036B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW106118838A 2016-06-07 2017-06-07 編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途 TWI752036B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US62/346,979 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US62/411,091 2016-10-21
US201662432005P 2016-12-09 2016-12-09
US62/432,005 2016-12-09

Publications (2)

Publication Number Publication Date
TW201808325A TW201808325A (zh) 2018-03-16
TWI752036B true TWI752036B (zh) 2022-01-11

Family

ID=59270113

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106118838A TWI752036B (zh) 2016-06-07 2017-06-07 編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途
TW110145699A TWI818375B (zh) 2016-06-07 2017-06-07 編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110145699A TWI818375B (zh) 2016-06-07 2017-06-07 編碼vegf-a多肽的經修飾rna、配製物及關於它們之用途

Country Status (25)

Country Link
US (1) US11866475B2 (enExample)
EP (2) EP3971204A1 (enExample)
JP (3) JP6859369B2 (enExample)
KR (4) KR102552543B1 (enExample)
CN (2) CN109790207B (enExample)
AU (2) AU2017277277B2 (enExample)
CA (1) CA3026500A1 (enExample)
CY (1) CY1124667T1 (enExample)
DK (1) DK3464338T3 (enExample)
ES (1) ES2895421T3 (enExample)
HR (1) HRP20211569T1 (enExample)
HU (1) HUE056055T2 (enExample)
IL (1) IL263370A (enExample)
LT (1) LT3464338T (enExample)
MA (1) MA45172B1 (enExample)
MX (1) MX2018015110A (enExample)
PL (1) PL3464338T3 (enExample)
PT (1) PT3464338T (enExample)
RS (1) RS62556B1 (enExample)
RU (1) RU2756313C2 (enExample)
SG (2) SG11201810816QA (enExample)
SI (1) SI3464338T1 (enExample)
SM (1) SMT202100586T1 (enExample)
TW (2) TWI752036B (enExample)
WO (1) WO2017214175A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3464338T (lt) 2016-06-07 2022-01-10 Modernatx, Inc. Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai
US11628227B2 (en) * 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
PL3703658T3 (pl) 2017-10-31 2022-08-22 Astrazeneca Ab Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a
US20220226243A1 (en) * 2019-05-08 2022-07-21 Astrazeneca Ab Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (en) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use
WO2023084013A1 (en) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2012138453A1 (en) * 2011-04-03 2012-10-11 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
EP1863516A2 (en) 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
WO2010065601A1 (en) * 2008-12-03 2010-06-10 Amorcyte, Inc. Infarct area perfusion-improving compositions and methods of vascular injury repair
CA2746003C (en) 2008-12-04 2020-03-31 Opko Curna, Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2012103985A2 (en) 2010-12-16 2012-08-09 Steve Pascolo Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
JP2015510495A (ja) 2011-12-21 2015-04-09 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 器官または器官移植片の生存可能性または寿命を延長する方法
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014152211A1 (en) * 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR102354389B1 (ko) 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
BR112016016416A2 (pt) * 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
LT3464338T (lt) 2016-06-07 2022-01-10 Modernatx, Inc. Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
MX389934B (es) 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
PL3703658T3 (pl) 2017-10-31 2022-08-22 Astrazeneca Ab Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2012138453A1 (en) * 2011-04-03 2012-10-11 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)

Also Published As

Publication number Publication date
HRP20211569T1 (hr) 2022-01-21
CA3026500A1 (en) 2017-12-14
SMT202100586T1 (it) 2021-11-12
KR20230107891A (ko) 2023-07-18
US20200407411A1 (en) 2020-12-31
CY1124667T1 (el) 2022-07-22
TWI818375B (zh) 2023-10-11
TW201808325A (zh) 2018-03-16
MX2018015110A (es) 2019-09-06
KR102552543B1 (ko) 2023-07-06
RU2018147229A (ru) 2020-07-10
IL263370A (en) 2018-12-31
SI3464338T1 (sl) 2022-02-28
AU2017277277B2 (en) 2023-05-04
JP6859369B2 (ja) 2021-04-14
JP2023011733A (ja) 2023-01-24
US11866475B2 (en) 2024-01-09
KR20220038819A (ko) 2022-03-29
EP3464338A1 (en) 2019-04-10
AU2023208200A1 (en) 2023-08-17
SG11201810816QA (en) 2018-12-28
CN109790207B (zh) 2023-06-20
RU2018147229A3 (enExample) 2020-09-23
EP3464338B1 (en) 2021-07-21
LT3464338T (lt) 2022-01-10
MA45172B1 (fr) 2021-11-30
JP2021100961A (ja) 2021-07-08
CN109790207A (zh) 2019-05-21
CN116606861A (zh) 2023-08-18
PT3464338T (pt) 2021-10-19
RS62556B1 (sr) 2021-12-31
AU2017277277A1 (en) 2019-01-03
DK3464338T3 (da) 2021-10-18
KR20190039066A (ko) 2019-04-10
HUE056055T2 (hu) 2022-01-28
SG10202012175YA (en) 2021-01-28
TW202218670A (zh) 2022-05-16
MA45172A (fr) 2019-04-10
PL3464338T3 (pl) 2021-12-27
KR102494499B1 (ko) 2023-01-31
EP3971204A1 (en) 2022-03-23
JP7167226B2 (ja) 2022-11-08
RU2756313C2 (ru) 2021-09-29
WO2017214175A1 (en) 2017-12-14
KR102376245B1 (ko) 2022-03-21
ES2895421T3 (es) 2022-02-21
KR20230019505A (ko) 2023-02-08
JP2019521976A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
JP7167226B2 (ja) Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用
Carlsson et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine
EA009390B1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
US20160193290A1 (en) Methods of Reducing Myocardial Injury Following Myocardial Infarction
HK40070904A (en) Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
CN117815369A (zh) 重组蛋白ccl11在治疗恶性胸腔积液中的应用
Wang et al. Recombinant human hepatocyte growth factor transfection alleviates hyperkinetic pulmonary artery hypertension in rabbit models
EP2964330B1 (en) Compositions and methods for cardiac tissue repair
HK40007104B (en) Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
US20230220026A1 (en) Nucleic acid carrier for producing the single-chain vegf fusion protein with high physiological stability and dimeric efficiency, preparation method thereof, and use thereof
Harris Illuminating Molecular Regulators of Lymphatic Endothelial Cell Signaling and Identity
WO2023061985A2 (en) Compositions comprising modified rna encoding vegf-a and methods of use
WO2006062087A1 (ja) 心筋障害又は心不全の治療もしくは予防組成物
CN116440163A (zh) 一种用于哺乳动物骨骼和/或肌肉抗衰的生物制品及其制备方法和应用
CN116098921A (zh) 一种具有哺乳动物大脑系统抗衰作用的生物制品及其制备方法和应用
CN1681525A (zh) 一种抑制血管渗漏和组织水肿的方法
Denby Cardiac Regeneration Following Myocardial Infarction in a Rat Model of Diabetic Cardiomyopathy
CN101068562A (zh) 治疗、预防、抑制或降低心脏组织损伤的方法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees